Endeavor Private Wealth Inc. Purchases Shares of 2,835 Astrazeneca Plc $AZN

Endeavor Private Wealth Inc. bought a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,835 shares of the company’s stock, valued at approximately $498,000.

A number of other large investors also recently modified their holdings of AZN. Brighton Jones LLC lifted its position in shares of Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Astrazeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares in the last quarter. Amundi lifted its position in shares of Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares in the last quarter. Jump Financial LLC lifted its position in shares of Astrazeneca by 898.4% during the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of Astrazeneca by 1.2% during the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after purchasing an additional 559 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Trading Up 0.1%

AZN opened at $186.06 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a market cap of $288.57 billion, a price-to-earnings ratio of 27.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. The firm has a 50 day simple moving average of $190.84 and a 200 day simple moving average of $185.34. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, sell-side analysts anticipate that Astrazeneca Plc will post 9.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.